论文部分内容阅读
作者采用自体LAK细胞和rIL-2腹腔内(IP)注射的方法,治疗24例病变局限于腹腔的恶性肿瘤患者。其中卵巢癌10例,结肠癌12例,子宫内膜癌1例及原发性小肠腺癌1例。全部卵巢癌、3例结肠癌及1例子宫内膜癌患者先前接受过其它抗癌治疗。患者接受静脉滴注IL-2 100000u/kg,每8小时1次,连续3天。2天后进行每天1次的白细胞分离,连续5天。LAK细胞是通过周围血单个核细胞在IL-2中体外孵育7天产生,然后通过Tenckhoff导管,每天腹腔内注射LAK
The authors used autologous LAK cells and rIL-2 intraperitoneal (IP) injections to treat 24 patients with lesions confined to the abdominal cavity. There were 10 cases of ovarian cancer, 12 cases of colon cancer, 1 case of endometrial cancer and 1 case of primary adenocarcinoma of the small intestine. All patients with ovarian cancer, 3 cases of colon cancer, and 1 case of endometrial cancer had previously received other anticancer treatments. The patient received intravenous infusion of IL-2 100000u/kg every 8 hours for 3 consecutive days. After 2 days, leucocytes were separated once a day for 5 consecutive days. LAK cells were generated by in vitro incubation of peripheral blood mononuclear cells in IL-2 for 7 days and then passed through the Tenchkhoff catheter and injected intraperitoneally with LAK daily.